Myriad Genetics Sees FY2026 Sales $860.000M-$880.000M vs $867.455M Est
Benzinga Newsdesk 8 months ago
NewsGuidance
Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 million analyst estimate.
Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 million analyst estimate.